Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?

about

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China.

P2860

Q36326867-AF3E3C15-32DA-4AC1-901D-7DFCE57EA81E Q38839367-B5847D97-7CAB-4F9B-A9B8-593854D64CF1

P2860

Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?

Item

http://www.wikidata.org/entity/Q38568358

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Post-autologous transplant mai ...... alignancies: are we there yet?

@en

type

Item

label

Post-autologous transplant mai ...... alignancies: are we there yet?

@en

prefLabel

Post-autologous transplant mai ...... alignancies: are we there yet?

@en

P1476

Post-autologous transplant mai ...... alignancies: are we there yet?

@en

P2093

H M Lazarus

http://www.w3.org/2001/XMLSchema#string

M Hamadani

http://www.w3.org/2001/XMLSchema#string

N Epperla

http://www.w3.org/2001/XMLSchema#string

T S Fenske

http://www.w3.org/2001/XMLSchema#string

P2860

Selective inhibition of BET bromodomains

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Oncogenically active MYD88 mutations in human lymphoma

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.

P2888

bmt.2015.184

P304

1393-1404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2015.184

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281142993

http://www.w3.org/2001/XMLSchema#string

P6179

1034938415

http://www.w3.org/2001/XMLSchema#string

P698

26281033

http://www.w3.org/2001/XMLSchema#string

Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?

about

P2860

P2860

Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P6179

P698